Cited by 309Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Open access

Kim, Ka Young, Shin, Ki Young, Chang, Keun-A·2023·Cells

DOI 10.3390/cells12091309PMC PMC10177296

Open this paper in CoChat — free account Open PDF

Abstract

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood biomarkers, recent studies have identified other reliable candidates that can serve as measurable indicators of pathological conditions. One such candidate is the glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein that can be detected in blood samples. Increasing evidence suggests that blood GFAP levels can be used to detect early-stage AD. In this systematic review and meta-analysis, we aimed to evaluate GFAP in peripheral blood as a biomarker for AD and provide an overview of the evidence regarding its utility. Our analysis revealed that the GFAP level in the blood was higher in the Aβ-positive group than in the negative groups, and in individuals with AD or mild cognitive impairment (MCI) compared to the healthy controls. Therefore, we believe that the clinical use of blood GFAP measurements has the potential to accelerate the diagnosis and improve the prognosis of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cells12091309

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system
Hol, E. M., & Pekny, M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.004 · Cited by 917
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T., Mulrow, C. D., Shamseer, L., Tetzlaff, J., Akl, E. A., Brennan, S., et al. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.112 · Cited by 761

Flagged first, then by citations

Show all 91 references

Research works printed but not linked: 2

Page, 2022, The PRISMA 2020 statement: An updated guideline for reporting systematic reviewsDeclaracion PRISMA 2020: Una guia actualizada para la publicacion de revisiones sistematicas, Rev. Panam. Salud Publica, 46, e112
Hansen, 2022, Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer’s Dementia, Fortschr. Neurol. Psyc, 90, 326

Sorted by citations

Items 101–200 of 309

Neurological Biomarker Profiles in Royal Canadian Air Force (RCAF) Pilots and Aircrew
Rhind, S. G., Shiu, M. Y., Vartanian, O. A., Allen, S., Palmer, M., Ramirez, J., Gao, F., Scott, C. J. M., Homes, M. F., Gray, G. W., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14121296 · Cited by 6
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network)
Sala, G., Cuffaro, L., Pozzi, F. E., Andreoni, S., Bazzini, C., Conti, E., Zoia, C., Beretta, S., Tremolizzo, L., Bellelli, G., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1581892 · Cited by 8
Virtual reality navigation for the early detection of Alzheimer’s disease
Shima, S., Ohdake, R., Mizutani, Y., Tatebe, H., Koike, R., Kasai, A., Bagarinao, E., Kawabata, K., Ueda, A., Ito, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1571429 · Cited by 7
Deciphering the Structural Biology of GFAP: Connotations of Its Potency in Presaging the Diagnosis for Traumatic Brain Injury and AD
Kanuri, S. H., & Sirrkay, P. J. (2025) · Neurology International · doi:10.3390/neurolint17090134 · Cited by 7
Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational Approaches
Godugu, D., Gattu, K., Suri, P., Daartey, A. B., Jadhav, K., & Rojekar, S. V. (2025) · Antibodies · doi:10.3390/antib15010001 · Cited by 6
Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: a nationwide population-based cohort study
Kang, D. W., Lee, J.-W., Park, M. Y., Kim, S., Um, Y. H., Wang, S., Lee, C. U., & Lim, H. K. (2024) · GeroScience · doi:10.1007/s11357-024-01284-z · Cited by 6
Transcriptional Patterns in Stages of Alzheimer's Disease Are Cell-Type–Specific and Partially Converge with the Effects of Alcohol Use Disorder in Humans
Joshi, A., Giorgi, F. M., & Sanna, P. P. (2024) · eNeuro · doi:10.1523/eneuro.0118-24.2024 · Cited by 6
Agomelatine attenuates dexamethasone-induced neurotoxicity in rats through the activation of MT1/2 receptors and attenuation of oxidative stress
Ali, N., Hasan, R. A., Ibrahim, I. A., & Mahmoud, M. F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177659 · Cited by 6
Central Nicotinic and Muscarinic Receptors in Health and Disease
Tizabi, Y., Getachew, B., Tsytsarev, V., Csoka, A. B., Copeland, R., & Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112447 · Cited by 8
Analysis of Speech Features in Alzheimer’s Disease with Machine Learning: A Case-Control Study
Noto, S., Sekiyama, Y., Nagata, R., Yamamoto, G., & Tamura, T. (2024) · Healthcare · doi:10.3390/healthcare12212194 · Cited by 9
Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis
Ghaderian, M., Shahbazi‐Gahrouei, D., Nikzad, S., Didehban, E., Hafezi, H., Laher, I., Beigi, F. H., Shahbazi‐Gahrouei, S., & Boustani, T. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.04.016 · Cited by 5
Sex-Associated Cerebellar and Hippocampal Volume Reduction in Alzheimer’s Disease: Insights from the Clinical ADNI Cohort and STZ Animal Model
Wartchow, K. M., Rodrigues, L., Dartora, W. J., Biasibetti, R., Selistre, N. G., Lazarian, A., Castellanos, C. B., Bartelo, N., Gonçalves, C., McIntire, L. B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104810 · Cited by 5
Neuro-Cells Mitigate Amyloid Plaque Formation and Behavioral Deficits in the APPswe/PS1dE9 Model of Alzheimer Disease While Also Reducing IL-6 Production in Human Monocytes
de Munter, J., Chaprov, K., Lang, E., Sitdikova, K., Wolters, E. C., Svirin, E. P., Kassenova, A., Tsoy, A., Kramer, B. W. W., Askarova, S., et al. (2025) · Cells · doi:10.3390/cells14151168 · Cited by 6
Decoding the neuroprotective potential of hesperidin: Insights into Alzheimer’s disease
Chauhan, P., Vadia, N., Ballal, S., Joshi, K. K., Maharana, L., Chauhan, A. S., Abomughaid, M. M., Lakhanpal, S., Avinash, D., Thakur, K., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.028 · Cited by 7
Performance of GFAP and UCH-L1 compared to S100B in detecting intracranial injury: influence of age, hemolysis, neurodegenerative diseases, and extracranial fractures in a prospective cohort of over 1,000 patients
Puravet, A., Sapin, V., Bouillon‐Minois, J., Pereira, B., Durif, J., Bouthors, B., Moustafa, F., Schmidt, J., Bouvier, D., & Oris, C. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1129 · Cited by 5
Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy
Shapiro, N. L., Jones, P. S., Mak, E., Tsvetanov, K. A., Goddard, J., Vontobel, D. S., Durcan, R., Chouliaras, L., Fryer, T. D., Hong, Y. T., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf467 · Cited by 6
Plasma GFAP as a mediator and moderator of Aβ, tau, and neurodegeneration in Alzheimer’s disease
Kim, J. S., Yi, D., Byun, M. S., Ahn, H., Jung, G., Choi, H., Lee, J., Kang, K. M., Chul-Ho, S., Lee, Y.-S., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00051-x · Cited by 5
Self-citation
Trauma exposure, PTSD, and methylation of the blood brain barrier claudin-5 gene
Wolf, E. J., Zhao, X., Madison, A. A., Carbaugh, J., Fortier, C. B., Milberg, W., Logue, M. W., & Miller, M. W. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107753 · Cited by 6
Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks
Pang, H., Frontera, J., Jiang, L., Li, C., Boutajangout, A., Sun, Z., Debure, L., Ghuman, M., Vedvyas, A., Masurkar, A. V., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71020 · Cited by 6
Norepinephrine-Activated p38 MAPK Pathway Mediates Stress-Induced Cytotoxic Edema of Basolateral Amygdala Astrocytes
Sun, Z., Zhang, X., Dong, Y., Liu, Y., Wang, C., Li, Y., Ma, C., Xu, G., Wang, S., Yang, C.-T., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14020161 · Cited by 4
The identification of a Distinct Astrocyte Subtype that Diminishes in Alzheimer’s Disease
Wei, H., Withrow, J. S., Rakshit, J., Amin, F. U., Nahm, J., Mowry, F. E., Mao, Z., Bhattacharjee, M. B., Zhu, J., Yang, Y., et al. (2024) · Aging and Disease · doi:10.14336/ad.2024.0205-1 · Cited by 7
mTBI Biological Biomarkers as Predictors of Postconcussion Syndrome—Review
Stępniewska, E., Kałas, M., Świderska, J., & Siemiński, M. (2024) · Brain Sciences · doi:10.3390/brainsci14050513 · Cited by 5
Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review
Jacob, C., Tollenaere, M., Kachar, H., Potier, M., Deyn, P. P. D., & Dam, D. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41445 · Cited by 6
New approach to specific Alzheimer's disease diagnosis based on plasma biomarkers in a cognitive disorder cohort
Álvarez‐Sánchez, L., Ferré‐González, L., Peña‐Bautista, C., Balaguer, Á., Amengual, J. L., Baquero, M., Cubas-Núñez, L., Casanova, B., & Cháfer‐Pericás, C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70034 · Cited by 6
Identification and Exploration of Immunity‐Related Genes and Natural Products for Alzheimer's Disease Based on Bioinformatics, Molecular Docking, and Molecular Dynamics
Liang, P., Wang, C. Y. Y., Liu, J., Huang, H., Li, Y., Kang, J., Li, G., & Wu, H. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70166 · Cited by 5
A Mouse Model of Sporadic Alzheimer’s Disease with Elements of Major Depression
Бобкова, Н. В., Chuvakova, L. N., Kovalev, V. I., Zhdanova, D. Y., Chaplygina, A. V., Rezvykh, A. P., & Evgen’ev, M. B. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04346-7 · Cited by 5
Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort study
Liang, C., Yan, X., Tian, J., Yang, Y.-Z., Xiao, X.-H., Huang, Y., & Wang, T.-F. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03001-y · Cited by 3
Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer’s disease in adults without dementia: a systematic review and meta-analysis protocol
Nihashi, T., Sakurai, K., Kato, T., Kimura, Y., Ito, K., Nakamura, A., & Terasawa, T. (2024) · Diagnostic and Prognostic Research · doi:10.1186/s41512-024-00167-3 · Cited by 5
Characterizing plasma and cerebrospinal fluid biomarkers relevant to neurodegeneration in captive olive baboons (Papio anubis)
Webb, S. J. N., Chitta, S., Magden, E. R., & Simmons, J. H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318173 · Cited by 4
Circulating Biomarkers of Neurodegeneration and Risk of Cognitive Impairment
Sawyer, R. P., Bennett, A., Blair, J. P., Judd, S. E., Olson, N. C., Howard, V. J., Armstrong, N. D., Long, D. L., Hyacinth, H. I., Manly, J. J., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213935 · Cited by 4
Intranasal Aβ1−42 Exposure Led To Neurobehavioral Alteration, Neuroinflammatory and Neurodegenerative Molecular Biomarkers in Mice Brain
Gautam, A. S., Akhtar, M. Z., Lasure, V., Kumari, N., Pandey, S. K., Dey, M., & Singh, R. K. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10246-x · Cited by 4
Blood-Based Tau as a Biomarker for Early Detection and Monitoring of Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110330 · Cited by 5
Self-citation
Clinical performance of scalable automated p‐tau 217 multi‐analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
Wilson, D. H., Copeland, K. A. F., Miller, M., Vasko, A., Hesterberg, L. K., Khare, M., Wolfe, M., Sheehy, P., Verberk, I. M. W., & Teunissen, C. E. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70215 · Cited by 4
Overactive Neuronal eEF2K/eEF2 signaling is associated with cognitive impairment and apathy-like behavior
Jester, H. M., Nicol, N. I., Yang, Q., Zhang, Y., Suhocki, A., Zhou, X., Underwood, E. B., Pourhadi, H., Cheng, D., Lee, J., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03408-z · Cited by 4
Influence of ApoE genotype on doxorubicin-induced cognitive impairment in juvenile rats
Patel, C., Diglio, F., Durham, B. H., & Cole, P. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-33104-5 · Cited by 4
Unlocking POCT potential: Multifunctional nano-enhanced lateral flow immunoassay for multiplexed detection of Alzheimer's disease biomarkers in diverse biological fluids
Chen, S., Li, C., Zhang, C., Zhao, S., Wang, Y., & Liu, Q. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217551 · Cited by 4
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 4
Blood-based biomarkers of Alzheimer's disease: potential utility in clinical practice
Zeng, X., Nicholson, N., & Karikari, T. K. (2026) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001475 · Cited by 4
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease
Cetindag, A. C., Schipke, C. G., Esselmann, H., Kruse, N., Wiltfang, J., Schneider, A., Fließbach, K., Miklitz, C., Maier, F., Büerger, K., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100544 · Cited by 5
A novel and mass-sensitive quartz tuning fork platform for glial fibrillary acidic protein determination
Özcan, B., Uludağ, İ., Ünal, M. A., Arı, F., Sezgintürk, M. K., & Özkan, S. A. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113408 · Cited by 4
Plasma Proteomic Analysis for Alzheimer’s Disease Biomarkers, Pathways, and Subgroup Identification
Peña‐Bautista, C., Álvarez‐Sánchez, L., Balaguer, Á., Ferré‐González, L., Peretó, M., Baquero, M., & Cháfer‐Pericás, C. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00513 · Cited by 4
Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies
Delva, A., Zatti, C., Pelletier, A., Montplaisir, J. Y., Gagnon, J., Kollmorgen, G., Kam‐Thong, T., Kustermann, T., Machado, V., & Postuma, R. B. (2025) · Movement Disorders · doi:10.1002/mds.70016 · Cited by 4
Preliminary reference values for Alzheimer’s disease plasma biomarkers in Congolese individuals with and without Alzheimer’s diseasePreprint
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2024) · medRxiv · doi:10.1101/2024.08.06.24311577 · Cited by 4
Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications
Jamerlan, A., An, S. S. A., & Hulme, J. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123325 · Cited by 3
Neurodegenerative plasma biomarkers for prediction of hippocampal atrophy in older adults with suspected Alzheimer's disease in Kinshasa, Democratic Republic of Congo
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251360697 · Cited by 3
Effects of Oral Anthocyanin Supplementation on In Vitro Neurogenesis, Hippocampus-Dependent Cognition, and Blood-Based Dementia Biomarkers: Results from a 24-Week Randomized Controlled Trial in Older Adults At Risk for Dementia (ACID)
de Lucia, C., Tovar, D., Khalifa, K. N., Kvernberg, S. M., Pola, I., Bergland, A. K., Maple‐Grødem, J., Siow, R. C. M., Ashton, N. J., Ballard, C. G., et al. (2025) · Nutrients · doi:10.3390/nu17162680 · Cited by 3
Early detection of Parkinson’s disease via aptamer-CRISPR platform
Madhusudhan, K., Padmanaban, A., & Parvathi, V. D. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.027 · Cited by 3
The blood lipidome fatty acid profile predicts the disease risk and clinical phenotypes of Alzheimer’s disease: associations from two prospective cohort studies
Liu, W.-Z., Huang, L., Chi, S., Ma, Y., Tan, C., Tan, L., Initiative, A. D. N., & Xu, W. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03526-w · Cited by 4
A dual-biomarker electrochemical immunosensor for plasma GFAP and pTau181 detection: Toward rapid and multiplexed screening of cognitive decline in stroke patients
Chien, S.-C., Lin, M.-J., Chang, M.-Y., Chen, Y.-C., Chang, C.-H., Wang, L.-C., & Chen, J.-C. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117337 · Cited by 3
Circulating Biomarkers of Neurodegeneration and All-Cause and Dementia-Specific Mortality
Sawyer, R. P., Blair, J. P., Judd, S. E., Olson, N. C., Howard, V. J., Armstrong, N. D., Long, D. L., Hyacinth, H. I., Sargent, L. J., Manly, J. J., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214752 · Cited by 4
Potential Protection Against Parkinson’s Disease by Ergothioneine—Nature’s Multifactorial Neuroprotectant
Tng, T. J. W., Cheah, I. K.-M., Halliwell, B. B., & Lim, K. (2026) · Antioxidants · doi:10.3390/antiox15040519 · Cited by 3
Acetylcholine - Recent Advances and New Perspectives
Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106304 · Cited by 3
Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ?
Delaby, C., & Lehmann, S. (2024) · médecine/sciences · doi:10.1051/medsci/2024037 · Cited by 3
Unveiling biomarker detection in Alzheimer’s disease: a computational approach to microarray analysis
Khan, N. S., Choudhary, S., Ali, M. S., Shawaz, M., Lohnes, B. J., & Poddar, N. K. (2024) · 3 Biotech · doi:10.1007/s13205-024-04159-4 · Cited by 3
Epigallocatechin -3- gallate mitigates diazinon neurotoxicity via suppression of pro-inflammatory genes and upregulation of antioxidant pathways
Onukak, C. E., Femi-Akinlosotu, O. M., Obasa, A. A., Folarin, O. R., Ajibade, T. O., Igado, O. O., Esan, O. O., Oyagbemi, T. O., Adeogun, A. V., Oyagbemi, A. A., et al. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00943-x · Cited by 4
Neuroprotective impacts of taurine nanoparticles against rotenone induced Parkinson’s disease in mice
Beltagy, D. M., Elgindy, K. M., Mohamed, T. M., Tousson, E., & Izzularab, B. M. (2025) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2547874 · Cited by 3
Peripheral risk factors and their role in biomarker‐based screening for dementia in the community
Hu, Y., Meirelles, O., Shiroma, E. J., Satizábal, C. L., Seshadri, S. S., Tracy, R. P., Gudnason, V. G., & Launer, L. J. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14293 · Cited by 3
Sex-specific neuroinflammatory responses to air pollution mediates cognitive performance in cognitively unimpaired individuals at risk of Alzheimer’s dementiaPreprint
Vilor‐Tejedor, N., Rodríguez‐Fernández, B., Genius, P., Fernández-Bonet, A., González‐Escalante, A., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Cumplido‐Mayoral, I., Minguillón, C., Cirach, M., et al. (2024) · medRxiv · doi:10.1101/2024.08.09.24311733 · Cited by 4
Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer’s disease brain tissuePreprint
Heberle, B. A., Fox, K. L., Libermann, L. L., Xavier, S. R. M., Dallarosa, G. T., Santos, R. C., Fardo, D. W., Viola, T. W., & Ebbert, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.07.622520 · Cited by 3
Beyond Molecular Weight: Peptide Characteristics Influencing the Sensitivity of Retention to Changes in Organic Solvent in Reversed-Phase Chromatography
Descamps, A., Hirmz, H., de Oliveira, E. C. L., Spiegeleer, A. D., Feio, J. A. S., da Costa, K. S., Spiegeleer, B. D., & Wynendaele, E. (2025) · ACS Omega · doi:10.1021/acsomega.5c02327 · Cited by 2
Cognitive and psycho-emotional disorders in children after traumatic brain injuries: Causes, clinical picture and therapy
Nesterovskiy, Y. E. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-305 · Cited by 2
INTEGRATIVE SYSTEMS BIOLOGY AND MULTI-OMICS APPROACHES IN ALZHEIMER'S DISEASE: BRIDGING BIOMARKERS, NEUROINFLAMMATION, AND PRECISION MEDICINE
Mathew, J., Maroky, A. S., SINDURAJ, S., & Chandrababu, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i5.54564 · Cited by 3
From the gut to the brain: Potential novel avenues for IBD treatment via serotonergic pathways
Ibgui, S., Lints, D., & Milling, S. W. F. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108059 · Cited by 2
Plasma biomarkers, brain amyloid‐beta pathology, and cortical thickness in a non‐Hispanic White and Black/African American middle‐aged community cohort: The HCP‐CoBRA study
Brodman, S. T., Heaton, N., Triana‐Baltzer, G., Zeng, X., Gogola, A., Kamboh, M. I., Villemagne, V. L., López, O. L., Kolb, H. C., Deek, R. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70985 · Cited by 2
Research Trends in Periodontitis and Alzheimer's Disease: A Bibliometric Analysis Based on Web of Science and Scopus
Chen, C., Chen, Q., Zou, H., Zhao, C., & Wang, X. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.109327 · Cited by 2
Neurobiological and neuroimaging biomarkers: A narrative review of precision medicine for diagnosing neurodegenerative disorders
Abbasi, A. A., Jokhio, F., Norouziyan, F., & Moradikor, N. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100150 · Cited by 2
USP53 promotes NOTCH2-induced neuroinflammation in Alzheimer's disease
He, D., Zhao, H., Zhu, Y., Kou, Y., Liu, T., Huang, H., Yang, H., Zhang, L., Deng, J., Xu, F., et al. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106109 · Cited by 3
When Alzheimer’s pathology meets cardiometabolic risk: intrinsic subcortical–cortical connectivity signatures of retroactive interference in aging
Altahona-Medina, M. A., Fernandez-Alvarez, M., Lopez-Vilaret, K. M., Rugg, M. D., Cantero, J. L., & Atienza, M. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01956-2 · Cited by 2
Systemic inflammation, delirium and clinical progression in mild-moderate Alzheimer disease
Dyer, A. H., Dolphin, H., Morrison, L., Kenny, T., Fallon, P. G., Cunningham, C. M., O’Connor, A., LAWLOR, B. A., O’Farrelly, C., Bourke, N. M., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106159 · Cited by 3
Nano-based spectroscopic approaches for early diagnosis of Alzheimer’s disease: critical insights into amyloid-β and tau biomarker biology and detection tools
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 2
Biomarker-targeted functionalized magnetic nanoparticles: synthesis and aptamer conjugation optimization toward Alzheimer's disease biosensing
Makridis, A., Kazeli, K., Katsipis, G., Tzekaki, E. E., Pantazaki, Α. A., Bosch, C., Carbajo, R. S., & Angelakeris, M. (2026) · Nanoscale Advances · doi:10.1039/d6na00021e · Cited by 2
Buntanetap treatment in mild to moderate Alzheimer’s disease: phase 2/3 study
Fang, C., Feng, D., Gaines, M., Laskowitz, D., Sanders, L. H., Liow, K. K., Peckham, E. L., Ritter, A., Chen, M., Morin, A., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00073-z · Cited by 2
Donanemab and lecanemab in Alzheimer's disease treatment: A narrative review of clinical trials and discussion of implications for patient access
Goswami, S., Masurkar, P. P., & Sherer, J. T. (2026) · Equity Neuroscience · doi:10.1016/j.neuros.2026.100057 · Cited by 2
Microglial senescence and epigenetic reprogramming in alzheimer's disease: An immunometabolic perspective
Ma, J., Yang, B., Jiang, X., Wang, L., Wei, W., Cao, Y., & Li, H. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113177 · Cited by 4
DTI-ALPS index and its association with neuroinflammatory and neurodegenerative biomarkers and tau-PET in Alzheimer’s continuum
Zafari, R., Kamroo, A., Taherkhani, T., Nabizdeh, F., & Aarabi, M. H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.010 · Cited by 3
Neuroinflammation in Alzheimer’s Disease (AD) and Glioblastoma (GBM): Shared Mechanisms and Therapeutic Insights
Mikołajczak, K., Chmiel, J., & Leszek, J. (2026) · Cells · doi:10.3390/cells15121111 · Cited by 2
Consensus statements for the diagnosis of mild traumatic brain injury and clinical integration of blood-based biomarkers in the Asia-Pacific region: a modified Delphi study
Kuan, W. S., Veerasarn, K., Joseph, M., Musikatavorn, K., Chung, K., Prasert, Y., Zairinal, R. A., Cordero, J. A., Shukla, D. P., & Mitra, B. (2026) · International Journal of Emergency Medicine · doi:10.1186/s12245-026-01292-0 · Cited by 2
Biomarkers Unveiling the Interplay of Mind, Nervous System, and Immunity
Doifode, T., Maziero, M. P., Quevedo, J., & Barichello, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4200-9_5 · Cited by 2
Single- versus two-test criteria for cognitive impairment: associations with CSF and imaging markers in former American football players
Ly, M. T., Altaras, C., Tripodis, Y., Adler, C. H., Balcer, L. J., Bernick, C. B., Zetterberg, H., Blennow, K., Peskind, E. R., Banks, S. J., et al. (2025) · The Clinical Neuropsychologist · doi:10.1080/13854046.2025.2451828 · Cited by 2
Risk of Alzheimer’s Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project CohortPreprint
Gu, Y., Honig, L. S., Kang, M. S., Bahl, A., Sanchez, D. L., Reyes‐Dumeyer, D., Manly, J. J., Lantigua, R., Dage, J. L., Brickman, A. M., et al. (2023) · medRxiv · doi:10.1101/2023.08.11.23293967 · Cited by 2
Plasma proteomic evidence for increased Alzheimer’s disease-related brain pathology after SARS-CoV-2 infectionPreprint
Duff, E. P., Zetterberg, H., Heslegrave, A., Dehghan, A., Elliott, P., Allen, N. E., Runz, H., Laban, R., Veleva, E., Whelan, C. D., et al. (2024) · medRxiv · doi:10.1101/2024.02.02.24302132 · Cited by 2
Plasma biomarkers, brain amyloid pathology, and cortical thickness in a diverse middle-aged community cohort: the HCP-CoBRA studyPreprint
Brodman, S. T., Heaton, N., Triana‐Baltzer, G., Zeng, X., Gogola, A., Kamboh, M. I., Villemagne, V. L., López, O. L., Kolb, H. C., Deek, R. A., et al. (2025) · medRxiv · doi:10.1101/2025.07.10.25331312 · Cited by 2
Multi-omics integration predicts 17 disease incidences in the UK BiobankPreprint
Du, J., Zhou, M., Raffield, L. M., Zhou, R., Li, Y., Chen, C., & Sun, Q. (2025) · medRxiv · doi:10.1101/2025.08.01.25332841 · Cited by 2
Advancements in Alzheimer’s Disease Biomarkers: Emerging Protein Targets for Early Diagnosis and Therapeutic Intervention
Khatun, M. M., Oni, M., Shadin, M., & Bodiuzzaman, B. S. M. (2025) · Journal of Medicinal Chemistry and Therapeutics · doi:10.71193/jmct.20250001 · Cited by 1
Global trends and prospects of ocular biomarkers in Alzheimer’s disease: a bibliometric analysis
Shen, Y., Zhang, X., Xu, C., & Zhu, Z. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1528527 · Cited by 1
Tacca chantrieri André Rhizome Extract Alleviates Scopolamine‐Induced Cognitive Impairment and Neuroinflammation in Rats
Hawiset, T., Sriraksa, N., Anukanon, S., Kamsrijai, U., Praman, S., Teerapattarakan, N., & Inkaew, P. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/7334303 · Cited by 1
Assessment of the combined utility of S100B, GFAP, and IL-6 in predicting long-term cognitive impairment in survivors of sepsis
Zhu, Z., He, C., Yao, H., Guqing, L., Gan, Y. X., & Deng, L. (2025) · Neurological Research · doi:10.1080/01616412.2025.2511084 · Cited by 1
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid
Minochkin, A. K., Lobzin, V. Y., Emelin, А. Y., Kopteva, Y. P., Клиценко, О. А., Апалько, С. В., & Shcherbak, S. G. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512504243 · Cited by 1
Magnetized water mitigates AlCl3-induced oxidative stress and Alzheimer's-like neurotoxicity in rats
Dawoud, S., El-Shazly, S. A., El-Refaiy, A. I., Ghamry, H. I., Sharaf-Eldin, A. M., Mostafa, A. A., Sofy, M. R., Sofy, A. R., El‐Magd, M. A., Zedan, A. M., et al. (2025) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2025.101660 · Cited by 1
Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: unraveling the interplay with risk of dementia
Vivek, S., Crimmins, E. M., Kim, J. K., Faul, J. D., Jacobs, D. R., Guan, W., & Thyagarajan, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-48115-z · Cited by 1
Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease
Chen, B. K., Hunsberger, H. C., Whye, A., Matthews, L. C., Yook, A., Willner, M. J., Logan, R., Johns, S., Weisblum, E., & Denny, C. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01804-9 · Cited by 2
Blood pressure dynamic instability and neurodegeneration in older adults
Lohman, T., Shenasa, F., Sible, I. J., Kapoor, A., Engstrom, A. C., Dutt, S., Head, E., Sordo, L., Alitin, J. P. M., Gaubert, A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251386443 · Cited by 1
Clinical effect of non-convulsive electroconvulsive therapy combined with olanzapine in patients with schizophrenia
Tao, K., Xiong, Q., & Wu, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1641908 · Cited by 1
Plasma biomarkers of alzheimer’s disease and related dementias are associated with cognitive change in community-dwelling older individuals in Australia and the US
Wu, Z., Mielke, M. M., Murray, A. M., Webb, K. L., Woods, R. L., Owen, A. J., Orchard, S. G., Chong, T. T. ‐., Sheets, K. M., & Ryan, J. L. (2025) · GeroScience · doi:10.1007/s11357-025-01985-z · Cited by 1
The Role of GFAP as a Marker of Astrocyte Activation in the Pathogenesis of Alzheimer's Dementia: A Literature Review
Sumadewi, K. T. (2025) · Health & Medical Sciences · doi:10.47134/phms.v3i1.519 · Cited by 1
Astrocyte–vascular interplay in Alzheimer's disease pathology: Novel insights into stage‐specific biomarkers and therapeutic targets
Sheng, Z.-H., Chen, Y., Chen, M., Liang, S., Wang, J., Chen, Y., Li, R., Xia, B., Gou, K., Liu, S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71122 · Cited by 1
Blood-based biomarkers and early diagnosis of Alzheimer’s disease
Cui, Z., Li, G., Wei, S., Cheng, Q., Yu, Q., Zong, S., Zhang, P., Chen, H., Yu, S., Wu, S., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00759 · Cited by 1
Environmental standard limit fluoride exposure prioritizes neurotoxicity over osteotoxicity in larval zebrafish: A benchmark dose analysis
Yang, X., Zhang, X., Jian, G., Zhu, Y., Chen, H., Mu, X., Li, J., Zhu, B., Lu, H., An, Y., et al. (2026) · Aquatic Toxicology · doi:10.1016/j.aquatox.2026.107749 · Cited by 1
The role of GDNF in neurodegenerative pathologies
Kolesnikova, A., Ushakova, V. M., Zorkina, Y., Andriushchenko, A., Zubkov, E. A., Chekhonin, V. P., & Kostyuk, G. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00234-z · Cited by 1
Role of astrocyte biomarker GFAP in early diagnosis and prognosis assessment of dementia: A comprehensive review
Li, S., Wei, S., Wang, L., Yu, T., Wang, H., Yang, S. B., Cao, W., & Zhang, X. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151452 · Cited by 1

Authors: Kim, K. Y., Shin, K. Y., & Chang, K.-A.
Affiliations: Gachon University (KR)
Seoul National University (KR)
Corresponding author: Shin, Ki Young
Chang, Keun-A
ORCID: Kim, Ka Young
Shin, Ki Young
Chang, Keun-A
Venue: Cells
Publisher: MDPI AG
Published: 2023-05-04
Volume: 12
Issue: 9
Pages: 1309
ISSN: 2073-4409 (ISSN-L)
DOI: 10.3390/cells12091309
PMC: PMC10177296
OpenAlex: W4376630140
Cited by: 309
References: 91
Citations by year: 2026: 93 · 2025: 126 · 2024: 80 · 2023: 10
FWCI: 14.11
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cells (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Research Foundation of Korea (NRF) (2022R1A2C1092597, 2020R1I1A1A01070793)
Basic Science Research Program through the NRF of Korea (2022R1A2C1092597, 2020R1I1A1A01070793)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: glial fibrillary acidic protein, Alzheimer's disease, blood biomarkers, peripheral blood, amyloid-beta, mild cognitive impairment, early diagnosis, prognosis, astrocytes
MeSH terms: Alzheimer Disease, Glial Fibrillary Acidic Protein, Humans, Biomarkers, Amyloid beta-Peptides, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks